US ACE Inhibitors Market

ID: MRFR/HC/17733-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US ACE Inhibitors Market Research Report: By Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), By Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease, Others), By Dosage Form (Oral Tablets, Oral Solution) and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites, Online Drug Stores) - Growth & Industry Forecast 2025 To 2035
US ACE Inhibitors Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.4%
2024 Market Size$ 1,166.07 Million
2025 Market Size$ 1,205.71 Million
2035 Market Size$ 1,684.77 Million
Key Players
Bristol-Myers Squibb
Novartis
Sanofi
Pfizer
Merck & Co.
AstraZeneca
Trends
  • Rising Prevalence of Cardiovascular Diseases
  • Innovations in Drug Formulations
  • Regulatory Support for New Treatments
Opportunities
  • Increasing Aging Population
  • Advancements in Telemedicine
  • Rising Healthcare Expenditure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Drug (USD Million)
      1. 4.1.1 Lisinopril
      2. 4.1.2 Ramipril
      3. 4.1.3 Enalapril
      4. 4.1.4 Benazepril
      5. 4.1.5 Fosinopril
      6. 4.1.6 Captopril
      7. 4.1.7 Moexipril
      8. 4.1.8 others
    2. 4.2 Security, Access Control and Robotics, BY Application (USD Million)
      1. 4.2.1 Heart Failure
      2. 4.2.2 Hypertension
      3. 4.2.3 Diabetes
      4. 4.2.4 Heart Attack
      5. 4.2.5 Chronic Kidney Disease
      6. 4.2.6 others
    3. 4.3 Security, Access Control and Robotics, BY Dosage Form (USD Million)
      1. 4.3.1 Oral Tablets
      2. 4.3.2 Oral Solution
    4. 4.4 Security, Access Control and Robotics, BY Distribution Channel (USD Million)
      1. 4.4.1 Retail Pharmacy
      2. 4.4.2 Hospital Pharmacy
      3. 4.4.3 E-commerce Websites
      4. 4.4.4 Online Drug Stores
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sanofi (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AstraZeneca (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Teva Pharmaceutical Industries (IL)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Lupin Pharmaceuticals (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Hikma Pharmaceuticals (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY DOSAGE FORM
    5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG, 2024 (% SHARE)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG, 2024 TO 2035 (USD Million)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Million)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DOSAGE FORM, 2024 (% SHARE)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DOSAGE FORM, 2024 TO 2035 (USD Million)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY DOSAGE FORM, 2025-2035 (USD Million)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US ACE Inhibitors Market Segmentation

US ACE Inhibitors Market By Drug (USD Million, 2025-2035)

  • Lisinopril
  • Ramipril
  • Enalapril
  • Benazepril
  • Fosinopril
  • Captopril
  • Moexipril
  • others

US ACE Inhibitors Market By Application (USD Million, 2025-2035)

  • Heart Failure
  • Hypertension
  • Diabetes
  • Heart Attack
  • Chronic Kidney Disease
  • others

US ACE Inhibitors Market By Dosage Form (USD Million, 2025-2035)

  • Oral Tablets
  • Oral Solution

US ACE Inhibitors Market By Distribution Channel (USD Million, 2025-2035)

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-commerce Websites
  • Online Drug Stores

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.